Clinical trial
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease…
NCT00240331 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00240331 |
|---|---|
| Title | AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD) |
| Official title | A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events (AURORA). A Double Blind, Randomised, Phase 3b, Parallel-group Study to Compare the Effects of Rosuvastatin With Placebo on Assessment of Survival & Cardiovascular… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Failure |
| Intervention type | Drug |
| Interventions | 10mg Rosuvastatin, Placebo |
| Enrollment | 2,776 |
| Start date | Jan 1, 2003 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Oct 18, 2005 |
| Last update posted | May 19, 2011 |
| Countries | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Greece and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: